The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.

What Was Tested

Researchers studied Gonadotropin-Releasing Hormone in this randomized controlled trial publication.

To determine whether there are any differences in the incidence of ovarian hyperstimulation syndrome (OHSS) and implantation rates in high-risk patients undergoing IVF using a protocol consisting of GnRH agonist trigger after cotreatment with GnRH antagonist or hCG trigger after dual pituitary suppression protocol.

Who Took Part

By PubMed's age tags, the people studied were adults, women only.

Sixty-six patients under 40 years of age with polycystic ovarian syndrome, polycystic ovarian morphology, or previous high response undergoing IVF.

Patients were randomized to an ovarian stimulation protocol consisting of either GnRH agonist trigger after cotreatment with GnRH antagonist (study group) or hCG trigger after dual pituitary suppression with a GnRH agonist (control group).

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Gonadotropin-Releasing Hormone study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

The subject headings attached to it are Contraceptives, Oral, Hormonal, Embryo Implantation, Estradiol, Fertility Agents, Female, Fertilization in Vitro, Gonadotropin-Releasing Hormone and Hormone Antagonists.

What This Means in Plain Language

The paper is a randomized study of Gonadotropin-Releasing Hormone.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2008 (Fertility and sterility), a journal based in United States.

More context: all human trials.